DAX24.217 +1,0%ESt505.378 +0,8%Top 10 Crypto16,29 +0,4%Dow44.623 -0,5%Nas21.137 -0,2%Bitcoin101.837 +0,2%Euro1,1551 -0,4%Öl72,78 +3,4%Gold3.327 +0,4%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Novo Nordisk A3EU6F NVIDIA 918422 Rheinmetall 703000 Heidelberger Druckmaschinen 731400 RENK RENK73 Lufthansa 823212 Volkswagen (VW) vz. 766403 Tesla A1CX3T PayPal A14R7U Deutsche Bank 514000 Mercedes-Benz Group (ex Daimler) 710000 BASF BASF11 DroneShield A2DMAA Amazon 906866 HENSOLDT HAG000
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX schließt deutlich im Plus -- Wall Street tiefer -- PayPal mit starkem Ergebnis -- D-Wave, Novo Nordisk, Uniper, UnitedHealth, Heidelberger Druckmaschinen, TeamViewer, Hypoport, Tilray im Fokus
Top News
Warum sich der Euro zum US-Dollar stabilisiert Warum sich der Euro zum US-Dollar stabilisiert
BioNTech-Aktie gibt nach: Partnerschaft mit Bristol Myers Squibb zur Fokussierung auf Krebsforschung BioNTech-Aktie gibt nach: Partnerschaft mit Bristol Myers Squibb zur Fokussierung auf Krebsforschung
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Ãœbersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
Deutscher Zertifikatepreis 2025: Jetzt abstimmen und attraktive Preise gewinnen!

Akebia Therapeutics Aktie

Handeln
Aktien-Sparplan anlegen
3,03 EUR +0,04 EUR +1,41 %
FSE
3,51 USD -0,10 USD -2,64 %
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.815,91 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1XF0S

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS00972D1054

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolAKBA

Akebia Therapeutics Aktien News

DatumMeistgelesen
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireAkebia Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireAkebia Therapeutics to Present at Piper Sandler Healthcare Conference
PR NewswireAkebia Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
PR NewswireAkebia Therapeutics Announces Favorable Payment Term Modification of Loan Agreement with Pharmakon Advisors
PR NewswireAkebia Therapeutics to Report Third Quarter 2023 Financial Results and Discuss Recent Business Highlights
PR NewswireAkebia Receives FDA Acceptance of Resubmission to NDA of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease
PR NewswireAkebia Therapeutics Announces Five Poster Presentations at ASN Kidney Week 2023
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireAkebia Therapeutics Resubmits New Drug Application to the FDA for Vadadustat
PR NewswireAkebia Announces Approval of Vafseo® (vadadustat) in Australia and Provides Commercial Update
PR NewswireAkebia Therapeutics to Present at H.C. Wainwright Global Investment Conference
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireAkebia Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
PR NewswireAkebia Therapeutics Expects to Resubmit Vadadustat NDA in Third Quarter 2023
PR NewswireAkebia Therapeutics to Report Second Quarter Financial Results and Discuss Recent Business Highlights
PR NewswireAkebia Therapeutics to Report Second Quarter Financial Results by August 25, 2023
PR NewswireAkebia Therapeutics Provides Update on Form 10-Q Filing
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireAkebia Therapeutics to Present at the H.C. Wainwright Kidney Conference
PR NewswireAkebia Therapeutics Completed Type A Meeting with the FDA and Expects to Resubmit Vadadustat NDA in Third Quarter 2023
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireAkebia Therapeutics Announces Positive Top-Line Results of Phase 4 IMPACT Study of Auryxia® (ferric citrate) for In-Center and Home Dialysis Patients
PR NewswireAkebia Announces Swissmedic Approval of Vafseo® (vadadustat)
PR NewswireAkebia Therapeutics Announces New Chief Financial Officer
PR NewswireAkebia Therapeutics to Present at Jefferies Healthcare Conference
PR NewswireFDA Provides Akebia Therapeutics a Path Forward for Vadadustat
PR NewswireAkebia Therapeutics Enters into License Agreement with Medice Arzneimittel Pütter GmbH&Co.KG for the Commercialization of Vafseo® for the Treatment of Anemia associated with CKD in Europe and Aust...
PR NewswireAkebia Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
PR NewswireAkebia Announces UK MHRA Approval of Vafseo® (vadadustat) for the Treatment of Symptomatic Anemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis
PR NewswireAkebia Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
PR NewswireAkebia Therapeutics to Report First Quarter Financial Results and Discuss Recent Business Highlights
PR NewswireAkebia Receives European Commission Approval for Vafseo™ (vadadustat) for the Treatment of Symptomatic Anaemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis
PR NewswireAkebia Therapeutics to Host Stockholder Information Session to Discuss Rationale for Reverse Stock Split
PR NewswireAkebia Therapeutics Announces Adjournment of Special Meeting of Stockholders
PR NewswireAkebia Therapeutics Announces Poster Presentations at National Kidney Foundation Spring Clinical Meetings 2023
PR NewswireAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireAkebia Therapeutics Announces Positive Top-Line Results from Vadadustat Alternative Dosing Study
PR NewswireAkebia Therapeutics Provides Update on Regulatory Process for Vadadustat

Akebia Therapeutics News

Akebia Therapeutics News: auf dieser Seite finden Sie alle Akebia Therapeutics News und Nachrichten zur Akebia Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Akebia Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Akebia Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.